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Background: The EVEREST II high surgical risk cohort included 351 high risk patients pooled from the EVEREST II High Risk Study and the EVEREST 
II REALISM Continued Access Study. As of July 2012, all patients completed 1 year follow-up and a subset of 211 patients completed 2 year follow-
up. One year outcomes on all 351 patients and two year results on the subset of 211 patients are reported.
methods: EVEREST II high surgical risk patients had 3+ or 4+ mitral regurgitation (MR) and were deemed high risk for surgery as predicted by 
a STS risk calculator operative mortality of ≥12%, or surgeon assessment based on pre-specified high surgical risk factors. Outcome measures 
included NYHA class, quality of life measures, hospitalizations for CHF, and echocardiographic measurements by an independent core lab.
results: Mean age of the patients was 76 ±11 years; baseline LVEF was 48%. Functional MR (FMR) was present in 70% and degenerative MR 
(DMR) in 30%. Baseline comorbidities included CHF (98%), CAD (82%), cardiomyopathy (58%), and previous cardiac surgery (60%). At baseline 85% 
of patients were in NYHA Class III/IV. Mean predicted surgical mortality by STS calculator was 11 ±8%. Freedom from mortality at 30 days and 12 
months was 95% and 77%, respectively. At 12 months, 83% of surviving patients experienced MR reduction to ≤2+ with significant reductions in LV 
volumes. In the subset of 211 patients through two-year follow-up, freedom from mortality was 64% and MR reduction was durable. A majority of 
patients had reduced symptoms, with 83% of patients in NYHA Class I/II at 12 months. Scores for the physical and mental components of the SF-36 
improved between baseline and 12 months. The annual rate of hospitalizations for CHF 12 months pre and post the MitraClip procedure was 0.79 
and 0.41, respectively (p<0.001). Safety and effectiveness of the MitraClip device in the subgroups of FMR and DMR etiologies were comparable.
conclusion: In high risk surgical patients, the MitraClip procedure resulted in significant and durable improvements in MR severity, significant 
improvements in LV remodeling, clinical relevant improvements in quality of life measures, and a significant reduction in re-hospitalization for CHF.
